BioMed Research International

BioMed Research International / 2015 / Article
!A Corrigendum for this article has been published. To view the article details, please click the ‘Corrigendum’ tab above.

Research Article | Open Access

Volume 2015 |Article ID 726012 | https://doi.org/10.1155/2015/726012

Catherina A. Cuevas, Cheril Tapia-Rojas, Carlos Cespedes, Nibaldo C. Inestrosa, Carlos P. Vio, "β-Catenin-Dependent Signaling Pathway Contributes to Renal Fibrosis in Hypertensive Rats", BioMed Research International, vol. 2015, Article ID 726012, 13 pages, 2015. https://doi.org/10.1155/2015/726012

β-Catenin-Dependent Signaling Pathway Contributes to Renal Fibrosis in Hypertensive Rats

Academic Editor: John J. Gildea
Received30 Nov 2014
Revised16 Mar 2015
Accepted17 Mar 2015
Published07 Apr 2015

Abstract

The mechanism of hypertension-induced renal fibrosis is not well understood, although it is established that high levels of angiotensin II contribute to the effect. Since -catenin signal transduction participates in fibrotic processes, we evaluated the contribution of -catenin-dependent signaling pathway in hypertension-induced renal fibrosis. Two-kidney one-clip (2K1C) hypertensive rats were treated with lisinopril (10 mg/kg/day for four weeks) or with pyrvinium pamoate (Wnt signaling inhibitor, single dose of 60 ug/kg, every 3 days for 2 weeks). The treatment with lisinopril reduced the systolic blood pressure from 220 ± 4 in 2K1C rats to 112 ± 5 mmHg (), whereas the reduction in blood pressure with pyrvinium pamoate was not significant (212 ± 6 in 2K1C rats to 170 ± 3 mmHg, ). The levels of collagen types I and III, osteopontin, and fibronectin decreased in the unclipped kidney in both treatments compared with 2K1C rats. The expressions of -catenin, p-Ser9-GSK-3beta, and the -catenin target genes cyclin D1, c-myc, and bcl-2 significantly decreased in unclipped kidney in both treatments (). In this study we provided evidence that -catenin-dependent signaling pathway participates in the renal fibrosis induced in 2K1C rats.

1. Introduction

Hypertension is a major risk factor for development and progression of chronic kidney disease [1]. The main consequence of the untreated hypertension is the chronic renal injury including vascular, glomerular, and tubulointerstitial injuries. Renal fibrosis is a hallmark of chronic hypertensive disease. Moreover, in animals and patients with chronic hypertension, the decline on renal function is correlated with the degree of renal fibrosis leading to end-organ failure [2]. Different factors have been involved in the pathophysiology of hypertension including the local overactivation of renin-angiotensin system (RAS) mainly by angiotensin II (Ang II) actions [3]. Studies using the model of Ang II-dependent hypertension have showed extensive glomerular and tubulointerstitial fibrosis [4]. In fact, it has been shown that the hypertension induced in 2K1C Goldblatt model is a consequence of increase in tissue Ang II content in both acute and chronic 2K1C animals [5].

Ang II works as a systemic vasoconstrictor, as a modulator of renal microcirculation, and as a regulator of sodium tubular transport [6]. However, Ang II seems to be a main contributor to progressive renal fibrosis through mechanisms participating in the production of chemotactic and profibrotic factors, recruitment of macrophages and myofibroblasts, and extracellular matrix protein production [7]. Chronic infusion of Ang II in murine models induces vascular and renal injuries with interstitial infiltration and increased collagen deposition [8, 9]. Additionally, it has been shown that Ang II is a potent upregulator of osteopontin (OPN), which acts as a chemoattractant molecule to promote fibroblast proliferation [10]. Moreover, in vitro studies have shown that Ang II stimulates fibronectin, TGF-β, CTGF, and PAI-1 synthesis [11]. Several models of kidney disease in both rodents and humans display local induction of the angiotensin converting enzyme (ACE) which is a well-known enzyme capable of forming Ang II from Ang I, providing an explanation for the elevated renal levels of Ang II in several pathological conditions [12]. In fact, ACE inhibitors (ACEi) or Ang II receptor antagonists are widely used for the treatment of the hypertension as they are known to have antifibrotic effects on the kidney [13].

The Wnt/β-catenin signaling pathway participates in organogenesis and tissue homeostasis, and its deregulation has been linked in the pathogenesis of human diseases, including cancers and degenerative diseases [14]. In the cell membrane, Wnt ligands transmit their signal through the interaction with Frizzled receptor and LRP5/6 coreceptor, initiating a series of molecular events leading to an increase in cytosolic β-catenin. The nuclear translocation of β-catenin allows its association with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors initiating the transcription of β-catenin-dependent target genes [15]. In the absence of Wnt ligands, the complex formed by APC-CKI-Axin-GSK-3β is assembled to form the destruction complex of β-catenin. Once the complex is assembled, the phosphorylation of β-catenin by glycogen synthase kinase-3β (GSK-3β) is the signal for ubiquitination and degradation by the proteasome system [14]. There are recent studies suggesting that the Wnt signaling pathway, mainly the β-catenin-dependent signaling, is altered and might have a role in fibrotic kidneys after obstructive injury (unilateral ureteral obstruction) [16]. In addition, it has been showed that several profibrotic genes, such as fibronectin, collagens, and OPN, are β-catenin target genes in different cellular contexts [1719]. However, whether the β-catenin signaling participates in the renal interstitial fibrosis induced by Ang II remains to be investigated. Recently, it was reported that β-catenin signaling was potently targeted by pyrvinium pamoate [20], an anthelmintic drug. This study was conducted in 2K1C Goldblatt hypertensive rats with the hypothesis that β-catenin-dependent signaling pathway contributes to renal fibrosis induced in this model.

2. Methods

2.1. Animals

All animal studies were performed in accordance with the Guiding Principles in the Care and Use of the Laboratory Animals for the American Physiological Society and were approved by the Ethics Committee of Animal Care of the Pontificia Universidad Católica de Chile. Animals were maintained at constant room temperature with a 12 h light/dark cycle in the institutional animal care facilities (PHS, NIH, OLAW, Animal Welfare Assurance #A5848-01) with free access to food and water.

2.2. 2K1C Goldblatt Hypertensive Rats and Treatments

Male Sprague-Dawley rats of 100–125 g were anesthetized with ketamine : xylazine i.p. (25 : 2.5 mg/kg) and a silver clip (0.20 mm) was placed around the left renal artery through a left flank incision. Animals were randomly divided into four groups (4 animals per group) according to the treatment: sham operated control, 2K1C rats without treatment, 2K1C rats treated with lisinopril (10 mg/kg/day) by oral gavage for four weeks starting from fourth week after surgery, and 2K1C rats treated with pyrvinium pamoate (60 μg/kg, single dose every 3 days) by oral gavage for 2 weeks starting from sixth week after surgery. The experiments with pyrvinium pamoate were subsequently performed to lisinopril experiments; therefore, each setting has its own sham control and 2K1C group. Pyrvinium pamoate was purchased from Sigma-Aldrich Co. (St. Louis, MO) and lisinopril was obtained from Recalcine CFR Pharmaceuticals. Systolic blood pressure (SBP) was measured at the end of experiments in conscious rats before the sacrifice using the tail-cuff plethysmography with a Grass polygraph. The rats were sacrificed at the end of 8th week after surgery by overdose of ketamine : xylazine. An independent group of 2K1C and sham rats ( per group) was formed with the purpose of monitoring the level of SBP throughout the experimental period (0–8 weeks). The unclipped kidney was immediately excised and frozen at −80°C or fixed in Bouin’s solution and processed for conventional histology, immunofluorescence, and immunohistochemistry.

2.3. Western Blot Analysis

Proteins were extracted from whole kidneys sections and were homogenized in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with protease and phosphatase inhibitors mixture. Proteins were separated by 10–12% SDS-PAGE and transferred to PVDF membranes. The membranes were blocked using 5% skim milk or BSA in 0.1% PBS-Tween for 1 hour at room temperature. The immunoblotting was performed using primary antibody against total β-catenin (# sc-7963, Santa Cruz Biotechnology, Santa Cruz, CA), active β-catenin clone 8E7 (# P35222, Millipore, Billerica, MA), total GSK-3β (# sc-9166, Santa Cruz Biotechnology, Santa Cruz, CA), p-Ser9-GSK-3β (# 93365, Cell Signaling, Danvers, MA), and the target genes cyclin D1, c-myc, and bcl-2 (# sc-717, sc-788, and sc-7382, respectively, Santa Cruz Biotechnology, Santa Cruz, CA) or fibronectin (# F3648, Sigma Aldrich, St. Louis, MO) and incubated overnight at 4°C. Proteins were detected using enhanced chemiluminescence techniques. The β-actin levels (# A1978, Sigma Aldrich, St. Louis, MO) were used as a load control and the densitometric analysis was performed using ImageJ (Wayne Rasband, National Institutes of Health, Bethesda, MD).

2.4. Immunostaining

Kidney tissue sections were fixed in Bouin’s solution and embedded in Paraplast Plus. The immunohistochemistry and immunofluorescence were carried out in 5 μm thick sections as previously done [21, 22]. Briefly, the tissue was dewaxed, rehydrated, rinsed in 0.05 mol/L Tris-phosphate-saline buffer pH 7.6, and then incubated overnight at 22°C with the primary antibody anti-collagen type III (Southern Biotech, Birmingham, AL), followed with appropriate secondary antibody and PAP complex (MP Biomedicals, Inc., Aurora, OH) was applied for 30 min. Samples incubated without primary antibody were used as negative control. Peroxidase activity was carried out with 0.1% (w/v) 3,3′-diaminobenzidine and 0.03% (v/v) hydrogen peroxide. Sections were counterstained with hematoxylin and then rehydrated, cleared with xylene, and mounted with Permount. Tissue sections were observed on a Nikon Eclipse E600 microscope and nonoverlapping images were photographed with a Nikon DS-Ri1 digital camera. For the immunofluorescence, the sections were incubated overnight at 4°C with the primary antibody anti-collagen type I or anti-OPN followed by Alexa Fluor 568 or 488, respectively (Invitrogen, Carlsbad, CA), and mounted with Vectashield (Vector Laboratories, Burlingame, CA). Nonoverlapping images were acquired using an Olympus BX51 fluorescence microscope and photographed with a Jenoptik ProgRes C5 digital camera. The stained area in each image was quantified utilizing computer-assisted image analysis software (Simple PCI, Hamamatsu). The values corresponding to total immunostained area were averaged and expressed as the mean absolute values per square micron and expressed as fold change compared to control values.

2.5. Statistical Analysis

The results are expressed as mean ± standard error (SEM). Differences between groups were assessed by a nonparametric Kruskal-Wallis test followed by Dunn’s multiple range test. Statistical tests were performed using the GraphPad Prism software v 5.0 (GraphPad Software Inc., San Diego, CA). A probability of 95% () was considered to be significant.

3. Results

3.1. Effect of ACE Inhibition on SBP and Renal Fibrosis in 2K1C Hypertensive Rats

Previously, the SBP through all experimental period was weekly evaluated in an independent group of 2K1C rats. SBP was significantly high in the third week after surgery ( mmHg, ) compared to sham rats at the same time ( mmHg, ). SBP of 2K1C rats continues to increase until fourth week ( mmHg) and remains high until eighth week ( mmHg) (Supplemental Figure S1 in Supplementary Material available online at http://dx.doi.org/10.1155/2015/726012).

In our experimental conditions, the SBP significantly decreased in rats treated for 4 weeks with lisinopril compared with 2K1C rats without treatment ( versus  mmHg, ) (Figure 1).

Renal fibrosis was evaluated by immunohistochemical staining for collagen type I, collagen type III, and OPN and the level of fibronectin protein by Western blot in the unclipped kidney. The unclipped kidneys from hypertensive rats showed a significant increased fibrosis assessed by deposition of collagen types I and III (Figures 2(a)-2(b), 2(d)-2(e), and 2(g)-2(h)) and it was associated with a significant increase in OPN immunostaining (Figures 3(a)3(d)) and fibronectin protein level (Figure 3(e)). The treatment of 2K1C hypertensive rats for four weeks with lisinopril significantly reduced the immunostaining for collagen types I and III (Figures 2(c), 2(f), and 2(g)) and OPN (Figures 3(c) and 3(d)) together with a decrease in the fibronectin protein level (Figure 3(e)).

3.2. Lisinopril Treatment Inhibits the β-Catenin Signaling Pathway in 2K1C Hypertensive Rats

To assess the status of the β-catenin signaling in 2K1C hypertensive rats and the effect of ACE inhibition, we evaluated the protein level of several components of the β-catenin signaling pathway by Western blot analysis in the unclipped kidney from 2K1C Goldblatt rats without treatment or treated with lisinopril. The protein levels of the β-catenin were significantly increased in unclipped kidney from hypertensive rats when compared to sham (, Figure 4). Interestingly, treatment with lisinopril restored the level of β-catenin to control values (Figure 4). Furthermore, we studied the expression of inactive form (p-Ser9) of GSK-3β and our results showed an increase in p-Ser9-GSK-3β in the unclipped kidney from 2K1C hypertensive rats compared to sham (Figure 5). The treatment with lisinopril significantly reduced this effect on GSK-3β phosphorylation (Figure 5, ). Moreover, we evaluated the levels of the classic β-catenin-dependent target genes such as cyclin D1, c-myc, and bcl-2. Our results indicated an increase in the level of cyclin D1, c-myc, and bcl-2 in the unclipped kidney from 2K1C hypertensive rats compared to sham (Figure 6). Interestingly, inhibition of ACE significantly reduced the protein levels of all of them (Figure 6).

3.3. Inhibition of β-Catenin Signaling Reduced Renal Fibrosis in 2K1C Hypertensive Rats

In order to test the hypothesis whether the β-catenin signaling is playing a role in the fibrosis we inhibited this signaling pathway using pyrvinium pamoate. The results showed that pyrvinium pamoate treatment significantly reduced the level of total β-catenin protein (Figure 7(a)) which is consistent with the reduction of the phosphorylation of GSK-3β in the inhibitory residue serine 9 (Figure 7(b)). Furthermore, in accordance with these results we observed a reduction of the expression of β-catenin-dependent gene products, cyclin D1 and bcl-2 (Figure 7(c)). We observed that the treatment with pyrvinium pamoate reduced SBP; nevertheless, this decrease was not statistically significant ( versus , , Figure 8). Immunostaining for collagen types I and III in renal tissue from unclipped kidney shows that inhibition of the β-catenin signaling significantly reduced the level of collagen types I and III (Figures 9(b)-9(c), 9(e)-9(f) and 9(g)-9(h)); similar reduction was observed in OPN levels as visualized by immunofluorescence (Figures 10(a)10(d)) and also observed in fibronectin level (Figure 10(e)) compared to 2K1C hypertensive rats.

4. Discussion

Our study demonstrated that β-catenin signaling pathway is activated and could play an important role in the development of kidney fibrosis secondary to hypertension in 2K1C hypertensive rats. We showed that treatment with an ACEi reduced the β-catenin signaling pathway along with a reduction of SBP and renal fibrosis compared with untreated hypertensive rats. Furthermore, we demonstrated that treatment with pyrvinium pamoate inhibits β-catenin signaling pathway and reduced renal fibrosis in hypertensive rats.

The 2K1C model is an established model of hypertension and it is dependent on the increased activity of RAS [5]. In accordance with previous studies, we recorded a continuous increase in SBP reaching a plateau after four weeks of surgery [23, 24]. Hypertension-induced renal failure is a progressive event associated with kidney remodeling characterized by fibrosis and alterations of renal function [25]. Our results indicated that 2K1C-induced hypertension was associated with renal fibrosis induction assessed by the increase in the levels of collagen types I and III, OPN, and fibronectin. Importantly, our data indicate that the increased collagen types I and III, fibronectin, and OPN levels in kidney from hypertensive rats were reduced after ACE inhibition, indicating that the RAS signaling is an important factor in the development of hypertension and fibrosis and also supporting the early notion from Guan et al. [26] that high levels of Ang II in the unclipped kidney result from enhanced ACE activity. The antifibrotic properties of ACEi have been shown in other models of renal fibrosis [27] as it is known that overactivation of RAS, mainly by the action of Ang II, is an important contributor to the pathogenesis of hypertension and it has profibrotic effects that contribute to the progression of chronic kidney disease [7].

Several pathways have been described as contributors in this process, including TGF-β/Smad signaling [28] as a main effector of Ang II-induced injury. However, the molecular mechanism remains unknown and the researches for effective treatments are still under development. Thus, search for new signal pathways and development of new therapeutic strategies are in progress. Recent studies have demonstrated that aberrant β-catenin signaling plays a key role in the development of organ fibrosis, suggesting it may be a novel therapeutic target in fibrotic disorders [29]. In agreement with previous studies showing the activation of β-catenin signaling in other models of renal injury [16], our data showed the increase of specific components of the β-catenin signaling in 2K1C hypertensive rats. Our results showed an increase in β-catenin levels together with the inhibition of GSK-3β and an increase in β-catenin-dependent gene products in the nonclipped kidney, suggesting the activation of this pathway in hypertensive rats. Interestingly, the upregulation of most of these gene products has been previously showed in obstructive uropathy renal damage model (UUO) [30, 31] and they participate in processes such as regulation of the cell cycle, cell proliferation, and apoptosis, among others. In addition, it has been showed that fibronectin [17], collagen types I and III [19, 32], and OPN [18] are all β-catenin target genes; therefore the upregulation of all these genes might account for the important role of β-catenin-dependent signaling in the control of adult tissue renewal and fibrosis. Despite that, we do not show regulation of the transcription factor TCF/LEF in our model; the upregulation of LEF-1 and TCF transcription factor has been demonstrated in the UUO rats [33, 34] and the colocalization of β-catenin with the transcription factor LEF-1 in the nuclei of podocytes has been shown in rats with focal glomerulosclerosis [35]; therefore it is conceivable that in 2K1C rats the interaction of β-catenin with TCF/LEF transcription factors could mediate the upregulation of its target genes.

On the other hand, as we mentioned previously, there is wide evidence suggesting that TGF-β is one of the main effectors of the Ang II-induced renal damage [10]. Using 2K1C model, Chen et al. (2011) [30] showed a decrease in the high levels of TGF-β in the nonclipped kidney after the treatment with enalapril. Coincidentally, the cross talk and cooperation between the Wnt/β-catenin signaling and TGF-β signaling pathways in the fibrotic processes have been showed [13, 25, 36]. Therefore, it is conceivable that the β-catenin signaling is a common effector of different pathways activated by Ang II to promote fibrosis in the kidney.

It is worth noting that our data showed that the ACE inhibition in 2K1C hypertensive rats was associated with an inhibition of the β-catenin signaling, suggesting a modulator role for RAS in this pathway. The levels of β-catenin, p-Ser9-GSK-3β, and the β-catenin-dependent gene products decreased after the treatment with lisinopril, suggesting that Ang II can stimulate the β-catenin signaling to promote the fibrosis in 2K1C hypertensive rats. A cross talk between the Ang II signaling and the β-catenin pathway appears to occur, since Ang II modulates GSK-3β phosphorylation inducing fibrosis in the heart [37]. However, additional experiments are needed to elucidate how Ang II modulates the β-catenin signaling pathway in the kidney. Recently, Zhou et al. (2015) [38] reported that all RAS genes are novel target genes of Wnt/β-catenin signaling pathway activation; it could suggest that the activation of this pathway contributes to maintaining the overactivation of RAS in chronic kidney disease.

Our results are in agreement with previous studies in UUO model of renal damage showing that inhibition of the Wnt/β-catenin signaling reduced renal β-catenin accumulation and decreased fibrosis [16, 39]. In our study, the inhibition of β-catenin signaling pathway reduces renal fibrosis in the unclipped kidney from 2K1C hypertensive rats. Furthermore, a novel finding in our study was the effect of pyrvinium pamoate (an FDA-approved drug) on reducing renal fibrosis in the unclipped kidneys. Recently, it was shown that pyrvinium pamoate may have therapeutic benefit in two different models of myocardial remodeling [40, 41] and here we are showing evidence of its potential therapeutic use in the hypertensive renal disease. Although Thorne et al. [20] showed that the β-catenin signaling was potently targeted by pyrvinium pamoate through the activation of casein kinase 1, novel mechanisms of action of pyrvinium pamoate have been suggested in different cancer cells lines, identifying pyrvinium pamoate as a novel anticancer drug able to target mitochondrial respiration in hypoglycemic/hypoxic conditions [42] and to inhibit the unfolded protein response induced by glucose starvation [43] and a noncompetitive androgen receptor inhibitor in prostate cancer cell lines. Despite the fact that our data strongly suggest that pyrvinium pamoate inhibits the β-catenin-dependent signaling pathway in 2K1C rats, the possibility that pyrvinium pamoate could also affect other cellular processes cannot be ruled out and future studies using a different β-catenin inhibitor may answer these questions.

Interestingly, our data showed that the treatment of hypertensive rats with pyrvinium pamoate treatment tends to decrease SBP; however, this decrease was not statistically significant; therefore, the animals remain exposed to high blood pressure levels. It is known that Ang II contributes to fibrotic lesions by the direct activation of profibrotic pathways in the kidney [7]. Furthermore, in UUO, which is a normotensive model of renal damage, Satoh et al. [44] showed that the Wnt/β-catenin signaling pathway is active in tubular cells as early as day 3 after UUO, and the activation of Wnt/β-catenin signaling pathway occurs independently of the increased blood pressure. Additional studies are required to better understand the contribution of the β-catenin signaling in the fibrotic lesions of unclipped kidney, in particular a Wnt/β-catenin signaling inhibitor without effect on blood pressure. However, we have recently provided evidence that in vitro Ang II induced the expression of profibrotic factors through the β-catenin-dependent signaling in mouse collecting duct cells. Ang II upregulated the β-catenin protein levels together with GSK-3β phosphorylation and β-catenin target genes. Interestingly, all these effects were prevented by pyrvinium pamoate, indicating that, in M-1 collecting duct cells, the β-catenin signaling pathway mediates the stimulation of fibrotic factors in response to AT1 receptor activation [36] independently of changes in blood pressure.

In summary, our findings suggest that β-catenin signaling pathway is active in fibrotic process in the unclipped kidney from 2K1C hypertensive rats. The inhibition of β-catenin signaling pathway by pyrvinium pamoate and lisinopril decreases renal fibrosis in 2K1C hypertensive rats. These findings provide a better understanding of the mechanisms involved in renal damage in hypertension and open new therapeutic approaches to control the fibrosis induced by hypertension.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors thank Maria Alcoholado for technical assistance in tissue processing. Catherina A. Cuevas and Cheril Tapia-Rojas have a doctoral fellowship from Comisión Nacional de Investigación Científica y Tecnológica (CONICYT). This work was supported by the Center of Excellence in Science and Technology CONICYT/PFB (12/2007) and grants from SQM Salar SA and Fondecyt 1130741.

Supplementary Materials

With the purpose of monitoring the level of systolic blood pressure (SBP) throughout the all experimental period (0-8 weeks) we performed an independent group of 2K1C and sham rats (n=8 rats per group) and the SBP was measured at 0, 3, 4 and 8 weeks after surgery. A significant increase on SBP was observed from the 3rd week after surgery. (p<0.05)

  1. Supplementary Figure

References

  1. H. T. Yu, “Progression of chronic renal failure,” Archives of Internal Medicine, vol. 163, no. 12, pp. 1417–1429, 2003. View at: Publisher Site | Google Scholar
  2. K. A. Griffin, “Hypertension and kidney damage,” Journal of Clinical Hypertension, vol. 8, no. 3, pp. 209–214, 2006. View at: Publisher Site | Google Scholar
  3. L. G. Navar, M. C. Prieto, R. Satou, and H. Kobori, “Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension,” Current Opinion in Pharmacology, vol. 11, no. 2, pp. 180–186, 2011. View at: Publisher Site | Google Scholar
  4. H. Haller, J. K. Park, D. Dragun, A. Lippoldt, and F. C. Luft, “Leukocyte infiltration and ICAM-1 expression in two-kidney one-clip hypertension,” Nephrology Dialysis Transplantation, vol. 12, no. 5, pp. 899–903, 1997. View at: Publisher Site | Google Scholar
  5. L. G. Navar, L. Zou, A. Von Thun, C. T. Wang, J. D. Imig, and K. D. Mitchell, “Unraveling the mystery of goldblatt hypertension,” News in Physiological Sciences, vol. 13, no. 4, pp. 170–176, 1998. View at: Google Scholar
  6. H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama, “The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease,” Pharmacological Reviews, vol. 59, no. 3, pp. 251–287, 2007. View at: Publisher Site | Google Scholar
  7. S. A. Mezzano, M. Ruiz-Ortega, and J. Egido, “Angiotensin II and renal fibrosis,” Hypertension, vol. 38, no. 3, part 2, pp. 635–638, 2001. View at: Publisher Site | Google Scholar
  8. D. M. Lombardi, M. Viswanathan, C. P. Vio, J. M. Saavedra, S. M. Schwartz, and R. J. Johnson, “Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor-dependent,” Nephron, vol. 87, no. 1, pp. 66–74, 2001. View at: Publisher Site | Google Scholar
  9. R. J. Johnson, C. E. Alpers, A. Yoshimura et al., “Renal injury from angiotensin II-mediated hypertension,” Hypertension, vol. 19, no. 5, pp. 464–474, 1992. View at: Publisher Site | Google Scholar
  10. A. R. Collins, J. Schnee, W. Wang et al., “Osteopontin modulates angiotensin II- induced fibrosis in the intact murine heart,” Journal of the American College of Cardiology, vol. 43, no. 9, pp. 1698–1705, 2004. View at: Publisher Site | Google Scholar
  11. A. Doller, S. Gauer, E. Sobkowiak, H. Geiger, J. Pfeilschifter, and W. Eberhardt, “Angiotensin II induces renal plasminogen activator inhibitor-1 and cyclooxygenase-2 expression post-transcriptionally via activation of the mRNA-stabilizing factor human-antigen R,” The American Journal of Pathology, vol. 174, no. 4, pp. 1252–1263, 2009. View at: Publisher Site | Google Scholar
  12. C. P. Vío and V. A. Jeanneret, “Local induction of angiotensin-converting enzyme in the kidney as a mechanism of progressive renal diseases,” Kidney International, Supplement, vol. 64, no. 86, pp. S57–S63, 2003. View at: Publisher Site | Google Scholar
  13. J. L. Bascands and J. P. Schanstra, “Bradykinin and renal fibrosis: have we ACE'd it?” Journal of the American Society of Nephrology, vol. 15, no. 9, pp. 2504–2506, 2004. View at: Publisher Site | Google Scholar
  14. N. C. Inestrosa and E. Arenas, “Emerging roles of Wnts in the adult nervous system,” Nature Reviews Neuroscience, vol. 11, no. 2, pp. 77–86, 2010. View at: Publisher Site | Google Scholar
  15. Y. Wang, Z. Sun, X. Qiu, Y. Li, J. Qin, and X. Han, “Roles of Wnt/β-catenin signaling in epithelial differentiation of mesenchymal stem cells,” Biochemical and Biophysical Research Communications, vol. 390, no. 4, pp. 1309–1314, 2009. View at: Publisher Site | Google Scholar
  16. W. He, C. Dai, Y. Li, G. Zeng, S. P. Monga, and Y. Liu, “Wnt/beta-catenin signaling promotes renal interstitial fibrosis,” Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 765–776, 2009. View at: Publisher Site | Google Scholar
  17. D. Gradl, M. Kühl, and D. Wedlich, “The Wnt/Wg signal transducer beta-catenin controls fibronectin expression,” Molecular and Cellular Biology, vol. 19, no. 8, pp. 5576–5587, 1999. View at: Google Scholar
  18. J. L. Viñas, A. Sola, M. Jung et al., “Inhibitory action of Wnt target gene osteopontin on mitochondrial cytochrome c release determines renal ischemic resistance,” American Journal of Physiology—Renal Physiology, vol. 299, no. 1, pp. F234–F242, 2010. View at: Publisher Site | Google Scholar
  19. C. M. Willis and M. Klüppel, “Chondroitin sulfate-E is a negative regulator of a pro-tumorigenic Wnt/beta-catenin-Collagen 1 axis in breast cancer cells,” PLoS ONE, vol. 9, no. 8, Article ID e103966, 2014. View at: Publisher Site | Google Scholar
  20. C. A. Thorne, A. J. Hanson, J. Schneider et al., “Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α,” Nature Chemical Biology, vol. 6, no. 11, pp. 829–836, 2010. View at: Publisher Site | Google Scholar
  21. C. P. Vio, M. Quiroz-Munoz, C. A. Cuevas, C. Cespedes, and N. R. Ferreri, “Prostaglandin E2 EP3 receptor regulates cyclooxygenase-2 expression in the kidney,” American Journal of Physiology—Renal Physiology, vol. 303, no. 3, pp. F449–F457, 2012. View at: Publisher Site | Google Scholar
  22. S. Villanueva, J. E. Carreño, L. Salazar et al., “Human mesenchymal stem cells derived from adipose tissue reduce functional and tissue damage in a rat model of chronic renal failure,” Clinical Science, vol. 125, no. 4, pp. 199–210, 2013. View at: Publisher Site | Google Scholar
  23. T.-T. Yu, K. Guo, H.-C. Chen et al., “Effects of traditional Chinese medicine Xin-Ji-Er-Kang formula on 2K1C hypertensive rats: role of oxidative stress and endothelial dysfunction,” BMC Complementary and Alternative Medicine, vol. 13, no. 1, article 173, 2013. View at: Publisher Site | Google Scholar
  24. L. Zhou, Y. Li, S. Hao et al., “Multiple genes of the renin-angiotensin system are novel targets of Wnt/β-catenin signaling,” Journal of the American Society of Nephrology, vol. 26, no. 1, pp. 107–120, 2015. View at: Publisher Site | Google Scholar
  25. A. Bohle, G. A. Muller, M. Wehrmann, S. Mackensen-Haen, and J.-C. Xiao, “Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides,” Kidney International, Supplement, vol. 54, pp. S2–S9, 1996. View at: Google Scholar
  26. S. Guan, J. Fox, K. D. Mitchell, and L. G. Navar, “Angiotensin and angiotensin converting enzyme tissue levels in two-kidney, one clip hypertensive rats,” Hypertension, vol. 20, no. 6, pp. 763–767, 1992. View at: Publisher Site | Google Scholar
  27. B. Liang and F. H. H. Leenen, “Prevention of salt induced hypertension and fibrosis by angiotensin converting enzyme inhibitors in Dahl S rats,” British Journal of Pharmacology, vol. 152, no. 6, pp. 903–914, 2007. View at: Publisher Site | Google Scholar
  28. H. Y. Lan, “Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation,” International Journal of Biological Sciences, vol. 7, no. 7, pp. 1056–1067, 2011. View at: Google Scholar
  29. Y. Guo, L. Xiao, L. Sun, and F. Liu, “Wnt/β-catenin signaling: a promising new target for fibrosis diseases,” Physiological research: Academia Scientiarum Bohemoslovaca, vol. 61, no. 4, pp. 337–346, 2012. View at: Google Scholar
  30. S.-C. Chen, J.-Y. Guh, T.-D. Lin et al., “Gefitinib attenuates transforming growth factor-beta1-activated mitogen-activated protein kinases and mitogenesis in NRK-49F cells,” Translational Research, vol. 158, no. 4, pp. 214–224, 2011. View at: Publisher Site | Google Scholar
  31. X. Qu, X. Zhang, J. Yao, J. Song, D. J. Nikolic-Paterson, and J. Li, “Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation,” The Journal of Pathology, vol. 228, no. 4, pp. 506–519, 2012. View at: Publisher Site | Google Scholar
  32. W.-S. Ge, Y.-J. Wang, J.-X. Wu, J.-G. Fan, Y.-W. Chen, and L. Zhu, “β-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell activation,” Molecular Medicine Reports, vol. 9, no. 6, pp. 2145–2151, 2014. View at: Publisher Site | Google Scholar
  33. L. Wang, Y.-F. Chi, Z.-T. Yuan et al., “Astragaloside IV inhibits the up-regulation of Wnt/beta-catenin signaling in rats with unilateral ureteral obstruction,” Cellular Physiology and Biochemistry, vol. 33, no. 5, pp. 1316–1328, 2014. View at: Publisher Site | Google Scholar
  34. K. Surendran and T. C. Simon, “CNP gene expression is activated by Wnt signaling and correlates with Wnt4 expression during renal injury,” American Journal of Physiology—Renal Physiology, vol. 284, no. 4, pp. F653–F662, 2003. View at: Publisher Site | Google Scholar
  35. M. A. Naves, L. R. Requião-Moura, M. F. Soares, J. A. Silva-Júnior, G. Mastroianni-Kirsztajn, and V. P. C. Teixeira, “Podocyte Wnt/β-catenin pathway is activated by integrin-linked kinase in clinical and experimental focal segmental glomerulosclerosis,” Journal of Nephrology, vol. 25, no. 3, pp. 401–409, 2012. View at: Google Scholar
  36. C. A. Cuevas, A. A. Gonzalez, N. C. Inestrosa, C. P. Vio, and M. C. Prieto, “Angiotensin II increases fibronectin and collagen I through the β-catenin-dependent signaling in mouse collecting duct cells,” The American Journal of Physiology—Renal Physiology, vol. 308, no. 4, pp. F358–F365, 2015. View at: Publisher Site | Google Scholar
  37. F. Hua, J. Zhou, J. Liu et al., “Glycogen synthase kinase-3β negatively regulates TGF-β1 and Angiotensin II-mediated cellular activity through interaction with Smad3,” European Journal of Pharmacology, vol. 644, no. 1–3, pp. 17–23, 2010. View at: Publisher Site | Google Scholar
  38. L. Zhou, Y. Li, S. Hao et al., “Multiple genes of the renin-angiotensin system are novel targets of Wnt/β-catenin signaling,” Journal of the American Society of Nephrology, vol. 26, no. 1, pp. 107–120, 2015. View at: Publisher Site | Google Scholar
  39. K. Surendran, S. Schiavi, and K. A. Hruska, “Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis,” Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2373–2384, 2005. View at: Publisher Site | Google Scholar
  40. S. Saraswati, M. P. Alfaro, C. A. Thorne, J. Atkinson, E. Lee, and P. P. Young, “Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling,” PLoS ONE, vol. 5, no. 11, Article ID e15521, 2010. View at: Publisher Site | Google Scholar
  41. M. Murakoshi, K. Saiki, K. Urayama, and T. N. Sato, “An anthelmintic drug, pyrvinium pamoate, thwarts fibrosis and ameliorates myocardial contractile dysfunction in a mouse model of myocardial infarction,” PLoS ONE, vol. 8, no. 11, Article ID e79374, 2013. View at: Publisher Site | Google Scholar
  42. E. Tomitsuka, K. Kita, and H. Esumi, “The NADH-fumarate reductase system, a novel mitochondrial energy metabolism, is a new target for anticancer therapy in tumor microenvironments,” Annals of the New York Academy of Sciences, vol. 1201, pp. 44–49, 2010. View at: Publisher Site | Google Scholar
  43. D.-H. Yu, J. Mcdonald, G. Liu et al., “Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy,” PLoS ONE, vol. 3, no. 12, Article ID e3951, 2008. View at: Publisher Site | Google Scholar
  44. M. Satoh, H. Nagasu, Y. Morita, T. P. Yamaguchi, Y. S. Kanwar, and N. Kashihara, “Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling,” American Journal of Physiology—Renal Physiology, vol. 303, no. 12, pp. F1641–F1651, 2012. View at: Publisher Site | Google Scholar

Copyright © 2015 Catherina A. Cuevas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1607 Views | 585 Downloads | 8 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.